# Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

> **NCT00419263** · PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 344 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Peramivir 150 mg
- **DRUG:** Peramivir 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00419263
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2015-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00419263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00419263, "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00419263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*